drugset / Trial / NCT06436274
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
Phase 4
Active not recruiting
778 enrolled
Massachusetts General Hospital
Botswana Harvard Health Partnership · collabFred Hutchinson Cancer Center · collabKarolinska Institutet · collabMinistry of Health, Rwanda · collabNational Cancer Institute (NCI) · collabUniversity of Witwatersrand, South Africa · collab
RandomizedCrossoverQuadruple-blindPrevention
Summary
The Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living with HIV: A Prospective, Individual, Double-Blind, Randomized Controlled Study is evaluating immediate or delayed single-dose nonavalent HPV vaccination among women living with HIV who received prior HPV vaccination.
Timeline
- Start
- 2024-10-14
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gardasil 9 | Vaccine | — | — |
| Subject | Menactra | Vaccine | — | — |
| Subject | Menveo | Vaccine | — | — |